• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants.

作者信息

Raz Michal Ariela, Arnason Jon, Bairey Osnat, Shvidel Lev, Aviv Ariel, Ben Baruch Sharon, Perry Chava, Sarid Nadav, Kirgner Ilya, Dvid Varon, Herishanu Yair, Avivi Irit

机构信息

Department of Internal Medicine T, Division of Internal Medicine, Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.

Department of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

出版信息

Br J Haematol. 2020 Apr;189(2):e31-e33. doi: 10.1111/bjh.16422. Epub 2020 Mar 9.

DOI:10.1111/bjh.16422
PMID:32150642
Abstract
摘要

相似文献

1
The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants.接受依鲁替尼联合新型直接口服抗凝剂治疗的患者的出血风险。
Br J Haematol. 2020 Apr;189(2):e31-e33. doi: 10.1111/bjh.16422. Epub 2020 Mar 9.
2
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.单药伊布替尼治疗的慢性淋巴细胞白血病患者中抗凝剂和抗血小板药物的使用
Br J Haematol. 2017 Jul;178(2):286-291. doi: 10.1111/bjh.14660. Epub 2017 Apr 10.
3
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.依鲁替尼相关出血：发病机制、管理及风险降低策略
J Thromb Haemost. 2017 May;15(5):835-847. doi: 10.1111/jth.13651. Epub 2017 Mar 27.
4
Risk of Major Bleeding with Ibrutinib.依鲁替尼导致大出血的风险。
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):755-761. doi: 10.1016/j.clml.2018.07.287. Epub 2018 Aug 1.
5
Ibrutinib-related bleeding: pathogenesis, clinical implications and management.依鲁替尼相关出血：发病机制、临床意义及管理
Blood Coagul Fibrinolysis. 2018 Sep;29(6):481-487. doi: 10.1097/MBC.0000000000000749.
6
Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.关于依鲁替尼治疗的心房颤动患者管理中抗凝剂选择的实用建议。
Leuk Lymphoma. 2017 Dec;58(12):2811-2814. doi: 10.1080/10428194.2017.1315115. Epub 2017 May 15.
7
Ibrutinib related bleeding complications in elderly patients with B cell malignancies.伊布替尼在老年B细胞恶性肿瘤患者中相关的出血并发症
J Thromb Thrombolysis. 2019 Nov;48(4):694-696. doi: 10.1007/s11239-019-01907-9.
8
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.依鲁替尼治疗患者大出血的发生率和风险因素：一项综合分析。
Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.
9
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.伊布替尼在真实世界中的实际管理：关注心房颤动和出血。
Hematol Oncol. 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7.
10
Perioperative Bleeding Associated With Ibrutinib in Dermatologic Surgery: A Case-Control Study.围手术期出血与皮肤科手术中的伊布替尼相关：一项病例对照研究。
Dermatol Surg. 2022 Nov 1;48(11):1166-1170. doi: 10.1097/DSS.0000000000003590. Epub 2022 Sep 8.

引用本文的文献

1
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: State-of-the-Art Review.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病中的心血管毒性：最新综述
JACC CardioOncol. 2023 Oct 17;5(5):570-590. doi: 10.1016/j.jaccao.2023.09.002. eCollection 2023 Oct.
2
Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions.衰弱患者癌症相关血栓的抗凝治疗：药物-药物相互作用管理中衰弱的影响。
Clin Pharmacokinet. 2023 Nov;62(11):1523-1531. doi: 10.1007/s40262-023-01298-4. Epub 2023 Oct 12.
3
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
接受伊布替尼和治疗性抗凝治疗的慢性淋巴细胞白血病患者的大出血发生率。
Leuk Lymphoma. 2023 Sep;64(9):1554-1561. doi: 10.1080/10428194.2023.2223740. Epub 2023 Jun 15.
4
Bleeding with concomitant ibrutinib and oral anticoagulant therapy: A population-based cohort study.依鲁替尼与口服抗凝剂联合治疗时的出血情况：一项基于人群的队列研究。
Am J Hematol. 2023 Mar;98(3):E49-E52. doi: 10.1002/ajh.26802. Epub 2022 Dec 7.
5
Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study.依鲁替尼与苯达莫司汀-利妥昔单抗治疗慢性淋巴细胞白血病时的大出血发生率：一项基于人群的队列研究。
Am J Hematol. 2022 Sep;97(9):E332-E335. doi: 10.1002/ajh.26632. Epub 2022 Jun 24.
6
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.B细胞恶性肿瘤患者中与伊布替尼相关的出血风险：随机对照试验的系统评价和荟萃分析
Front Pharmacol. 2020 Nov 20;11:580622. doi: 10.3389/fphar.2020.580622. eCollection 2020.